J Am Heart Assoc:控制血压可减少房颤患者卒中的发生(ARISTOTLE研究)

2015-12-10 phylis 译 MedSci原创

背景:房颤(AF)和高血压是卒中发生的高危因素。以往研究表明。存在高血压史(不管血压控制情况)的房颤患者,及血压升高的患者卒中发生的风险增加。研究者评估了高血压及高血压控制对临床预后的相关性。方法和结果:ARISTOTLE(n = 18201),评估血压确定需要治疗的高血压及进入研究和实验过程中血压升高(收缩压≥140及/或舒张压≥90mm Hg)。血压为时间依赖协变量,应用Cox比例风险模型计算

背景:房颤(AF)和高血压是卒中发生的高危因素。以往研究表明。存在高血压史(不管血压控制情况)的房颤患者,及血压升高的患者卒中发生的风险增加。研究者评估了高血压及高血压控制对临床预后的相关性。

方法和结果:ARISTOTLE(n = 18201),评估血压确定需要治疗的高血压及进入研究和实验过程中血压升高(收缩压≥140及/或舒张压≥90mm Hg)。血压为时间依赖协变量,应用Cox比例风险模型计算HR值。

15916(87.5%)名患者有高血压病史,需要治疗。试验期间,在任何点血压测量升高的患者,卒中或全身性栓塞率明显升高(HR,1.53;95% CI,1.25-1.86),出血性卒中和缺血性脑卒中发生的HR分别为HR 1.85(95% CI,1.26-2.72),HR,1.50 (95% CI,1.18-1.90)。高血压史的患者(HR,0.80;95% CI,0.66-0.98)严重出血的发生较低,进入研究血压升高的患者(HR,0.89;95% CI,0.77-1.03)严重出血的发生没有明显下降。有无高血压史的患者,有无血压基线控制及有无试验中血压控制,应用阿哌沙班与华法林预防卒中或全身性栓塞的益处是一致的。

结论:试验中任一时间点测量的血压升高与卒中或全身性栓塞的风险升高相关。这些结果显示治疗升高的血压是降低房颤患者发生卒中的重要措施。

原文出处:

Rao MP, Halvorsen S, Wojdyla D, et al. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With Atrial Fibrillation: Results From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015 Dec 1.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2016-01-09 medsic

    只是血压的控制标准总是有有待进一步肯定……

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2016-01-09 medsic

    还是要赞一下的,

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2016-01-09 medsic

    继续关注!

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2016-01-09 medsic

    嗯,

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2016-01-09 medsic

    不错,

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    好文章,值得看。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2015-12-13 yuwenpsy

    ………

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1988321, encodeId=da231988321f4, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Wed Jun 08 10:30:00 CST 2016, time=2016-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780021, encodeId=84c21e800214e, content=<a href='/topic/show?id=50b42e6504' target=_blank style='color:#2F92EE;'>#ARISTOTLE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2765, encryptionId=50b42e6504, topicName=ARISTOTLE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri May 20 18:30:00 CST 2016, time=2016-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55283, encodeId=084a55283b0, content=只是血压的控制标准总是有有待进一步肯定……, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55284, encodeId=6ce15528441, content=还是要赞一下的,, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55285, encodeId=c2bc55285d8, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=141, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:04:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55281, encodeId=c6ac5528190, content=嗯,, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=55282, encodeId=f66a552822b, content=不错,, beContent=null, objectType=article, channel=null, level=null, likeNumber=198, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=32ba1611217, createdName=medsic, createdTime=Sat Jan 09 23:03:00 CST 2016, time=2016-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48556, encodeId=30ae48556fd, content=好文章,值得看。, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 17:33:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45820, encodeId=340945820e5, content=………, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=554a1670659, createdName=yuwenpsy, createdTime=Sun Dec 13 22:37:00 CST 2015, time=2015-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356042, encodeId=7a801356042db, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Dec 12 06:30:00 CST 2015, time=2015-12-12, status=1, ipAttribution=)]
    2015-12-12 zhaojie88

相关资讯

JACC:房颤患者服用利伐沙班会增加胃肠道出血风险

胃肠道(GI)出血是口服抗凝药的常见并发症。在ROCKET AF(在房颤患者中预防卒中和栓塞试验中,生素K拮抗预防与利伐沙班每日一次口服直接Xa因子抑制进行了比较)治疗组试验中,研究人员评估了接受至少1种剂量研究药物患者GI出血情况。主要结果判定第一个到最后一个药物剂量+2天时GI出血的报道。研究人员使用预先指定的预测变量进行多变量模型检测。14236名患者中,684例患者在随访期间出现胃肠道出血

PLoS ONE:非酒精性脂肪肝中年患者易发生房颤(OPERA研究)

芬兰Oulu大学医院内科研究中心Aki J Karajamaki和同事研究非酒精脂肪肝与中年人群房颤之间的关系(OPERA研究),发现非酒精脂肪肝是中年人群房颤的预测因素。研究结果2015年11月16日在PLoS ONE在线发表。

Thromb Haemost:房颤患者左心房血栓发生的meta分析

研究者对房颤(AF)患者左心房血栓(LAT)发生的发生进行了meta分析,对AF患者行经食管超声心动图(TEE)检查是否存心左心房血栓。系统性搜索了PubMed,Web of Science,Scopus及EMBASE数据库进行研究AF患者LAT的发生,总LAT的发生应用加权平均患病率来评估(WMP)。72个研究(20516名AF患者)LAT的WMP为9.8 %(95 % CI:7.6 % - 1

BMJ:抗血栓和抗出血该如何平衡?

患有非瓣膜性心房颤动的病人以及有血栓栓塞风险的需要接受抗凝血治疗以降低卒中发生的风险。但是,抗凝血治疗会带来一种严重的并发症,即增加出血的风险,尤其是胃肠道出血。当病人在接受抗血栓栓塞治疗期间经历了胃肠道出血后,临床医生就很容易处于一个两难的境地,是否应该重新治疗?

JAMA:房颤筛查帮助降低卒中风险

图片来源:infoaboutsymptoms.com 近日,来自悉尼大学的研究人员通过研究表明,对65岁及以上的个体进行无症状的房颤筛查并且利用抗凝药物进行治疗或许可以极大程度地降低个体因卒中死亡和过早死亡的风险,相关研究刊登于国际杂志Journal of the American Medical Association上。 心房颤动(AF)是一种异常的心脏节律,其会给患者带来心脏血栓的风

Age Ageing:老年房颤患者预防卒中应用阿哌沙班 or 阿司匹林?

背景:随着年龄增加,房颤(AF)的发生增加,并且卒中及出血的风险增加。研究者报到了不适用维生素K拮抗剂的房颤患者,应用阿哌沙班VS乙酰水杨酸(ASA)对高龄患者(≥75岁及≥85)及年轻患者的影响。方法:AVERROES试验(阿哌沙班VS ASA预防不适用维生素K拮抗剂治疗预防房颤患者卒中发生)试验(n = 5599),患者1898例≥75岁,366例患者≥85岁。研究者比较不同年龄的基线特征,及